Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -1.50 is 38% above its 5-year average of -2.41, near the high end of its 5-year range (-4.42–-0.53).
39.64% above its 12-month average of -2.49.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.26.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 21 comparable quarters.
EARNINGS PER SHARE (EPS)
-1.50
EARNINGS PER SHARE (EPS) AVG TTM
-2.49
EARNINGS PER SHARE (EPS) AVG 3Y
-3.17
EARNINGS PER SHARE (EPS) AVG 5Y
-2.41
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+39.64%
CURRENT VS 3Y AVG
+52.72%
CURRENT VS 5Y AVG
+37.67%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
PepGen Inc.
Market Cap
$159.78M
Earnings Per Share (EPS)
-1.50
TTM Avg
-2.49
3Y Avg
-3.17
5Y Avg
-2.41
Market Cap
$159.80M
Earnings Per Share (EPS)
-28.87
TTM Avg
-17.24
3Y Avg
-11.28
5Y Avg
-9.01
Market Cap
$159.22M
Earnings Per Share (EPS)
-0.51
TTM Avg
-0.38
3Y Avg
-0.76
5Y Avg
-1.59
Market Cap
$159.14M
Earnings Per Share (EPS)
-1.02
TTM Avg
-0.60
3Y Avg
-1.87
5Y Avg
-1.57
Market Cap
$162.04M
Earnings Per Share (EPS)
-2.63
TTM Avg
-1.75
3Y Avg
-1.74
5Y Avg
-1.61
Market Cap
$156.22M
Earnings Per Share (EPS)
-0.90
TTM Avg
-1.19
3Y Avg
-2.61
5Y Avg
-1.83
Market Cap
$165.27M
Earnings Per Share (EPS)
-1.57
TTM Avg
-1.50
3Y Avg
-2.00
5Y Avg
-2.13
Market Cap
$165.32M
Earnings Per Share (EPS)
0.23
TTM Avg
-0.41
3Y Avg
-0.62
5Y Avg
-0.44
Market Cap
$153.79M
Earnings Per Share (EPS)
-0.43
TTM Avg
-0.98
3Y Avg
-1.10
5Y Avg
-1.18
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PepGen Inc. (PEPG) | $159.78M | -1.50 | -2.49 | -3.17 | -2.41 |
| Minerva Neurosciences, Inc. (NERV)vs › | $159.80M | -28.87 | -17.24 | -11.28 | -9.01 |
| LifeMD, Inc. (LFMDP)vs › | $159.22M | -0.51 | -0.38 | -0.76 | -1.59 |
| Coherus Oncology, Inc. (CHRS)vs › | $159.14M | -1.02 | -0.60 | -1.87 | -1.57 |
| Quanterix Corporation (QTRX)vs › | $162.04M | -2.63 | -1.75 | -1.74 | -1.61 |
| Inogen, Inc. (INGN)vs › | $156.22M | -0.90 | -1.19 | -2.61 | -1.83 |
| Nkarta, Inc. (NKTX)vs › | $165.27M | -1.57 | -1.50 | -2.00 | -2.13 |
| OptimizeRx Corp. (OPRX)vs › | $165.32M | 0.23 | -0.41 | -0.62 | -0.44 |
| Neuronetics, Inc. (STIM)vs › | $153.79M | -0.43 | -0.98 | -1.10 | -1.18 |
| Jyong Biotech Ltd. Ordinary Shares (MENS)vs › | $153.58M | N/A | -0.05 | -0.06 | -0.06 |
Trailing EPS (TTM)
$-1.50
Forward EPS (Est.)
$-1.06
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.12 |
| 2024-12-31 | -2.85 |
| 2023-12-31 | -3.30 |
| 2022-12-31 | -4.42 |
| 2021-12-31 | -1.22 |
| 2020-12-31 | -0.53 |
| 2019-12-31 | -0.06 |
